Clinical Trial Detail

NCT ID NCT03323034
Title Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Children's Oncology Group
Indications

central nervous system cancer

Advanced Solid Tumor

lymphoma

Therapies

Irinotecan + MLN4924 + Temozolomide

Age Groups: child adult

No variant requirements are available.